|
14 Feb 2019 |
Abilita Bio and Amgen Enter Into a Multi-Target Collaboration
|
|
14 Feb 2019 |
Glenmark to spin off its innovation business into a new company in the US
|
|
14 Feb 2019 |
Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria
|
|
12 Feb 2019 |
Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab
|
|
12 Feb 2019 |
3SBio and Verseau Establish Global Clinical Development Collaboration for First-in-class Immuno-Oncology Therapies
|
|
12 Feb 2019 |
AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma
|
|
11 Feb 2019 |
Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare
|
|
11 Feb 2019 |
UCB and Epilepsy Society announce pioneering UK Genomics R&D collaboration
|
|
11 Feb 2019 |
Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China
|
|
07 Feb 2019 |
Evotec and Galapagos enter into collaboration in the field of fibrosis
|
|
05 Feb 2019 |
Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech
|
|
05 Feb 2019 |
Merck and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Immunotherapy with Potential in Multiple Difficult-to-Treat Cancers
|
|
05 Feb 2019 |
ProteoNic Biotechnology Licenses Protein Production Technology to Eli Lilly and Company
|
|
04 Feb 2019 |
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology
|
|
01 Feb 2019 |
I-Mab Biopharma and Bio-Cancer Treatment International Announce Intention for Collaboration on Arginine Depletion Therapy and Biomarker Study, with Plans for I-Mab to Establish a Translational Medicine Lab in Hong Kong
|
|
01 Feb 2019 |
Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases
|
|
01 Feb 2019 |
Alexion and Caelum Biosciences Announce Collaboration to Develop Targeted Therapy for Light Chain (AL) Amyloidosis
|
|
01 Feb 2019 |
Invenra and WARF Initiate a Collaboration to Discover and Develop Novel Therapeutics to Fight Neuroblastoma in Children
|
|
31 Jan 2019 |
Repare Therapeutics Announces a Strategic Partnership Agreement With ONO Pharmaceutical Co., Ltd. for Repare’s Polθ Inhibitor Program in Japan and Selected Territories in Asia
|
|
29 Jan 2019 |
Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
|
|
29 Jan 2019 |
Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia
|
|
29 Jan 2019 |
FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy
|
|
29 Jan 2019 |
Purdue Pharma L.P. and Alivio Therapeutics Enter into Partnership to Advance ALV-107, a Non-Opioid Interstitial Cystitis/Bladder Pain Syndrome Treatment
|
|
24 Jan 2019 |
Origenis GmbH Announces Global License and Collaboration Agreement with Expansion Therapeutics for Novel Therapies Targeting RNA-mediated Diseases
|
|
24 Jan 2019 |
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
|
